Unveiling the potential of HSPA4 - a comprehensive pan-cancer analysis of HSPA4 in diagnosis, prognosis, and immunotherapy

Sep 21, 2026

Uploaded by Finn

With the global rise in cancer incidence and mortality, understanding heat shock protein pathways has become urgent. This study focuses on HSPA4, a member of the HSP70 family, noting that prior work on HSPA4 is often cancer-type specific. Using bioinformatics methods, the analysis evaluates HSPA4’s diagnostic and prognostic value, links genetic variation and methylation to tumorigenesis, and examines its associations with immune cells and the tumor microenvironment to support immunotherapy relevance.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages25

Reading Time1 h 3 min

AccessFree to download

Abstract

Introduction

[www.aging-us.com](www.aging-us.com) AGING 2024, Vol. 16, No. 3 Research Paper Unveiling the potential of HSPA4: a comprehensive pan-cancer analysis of HSPA4 in diagnosis, prognosis, and immunotherapy Junhao Yang1,*, Xiaoxiao Wu2,*, Jianhong You3 1 Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang 110001, China 2 Department of Rheumatology, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310000, China 3 Department of Ultrasound, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361000, China *Equal contribution Correspondence to: Jianhong You; [email:](email: youjh9877@163.com)[ ](email: youjh9877@163.com)[youjh9877@163.com](email: youjh9877@163.com), [https://orcid.org/0000-0002-8522-9407](https://orcid.org/0000-0002-8522-9407)[ ](https://orcid.org/0000-0002-8522-9407)[Keywords:](Keywords: HSPA4)[ HSPA4](Keywords: HSPA4), pan-cancer, bioinformatics, immunotherapy, prognosis Received: October 2, 2023 Accepted: January 3, 2024 Published: January 31, 2024 Copyright: © 2024 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT With the global rise in cancer incidence and mortality rates, research on the topic has become increasingly urgent. Among the significant players in this field are heat shock proteins (HSPs), particularly HSPA4 from the HSP70 subfamily, which has recently garnered considerable interest for its role in cancer progression. However, despite numerous studies on HSPA4 in specific cancer types, a comprehensive analysis across all cancer types is lacking. This study employs various bioinformatics techniques to delve into the role of HSPA4 in pan-cancer. Our objective is to assess its potential in clinical diagnosis, prognosis, and as a future molecular target for therapy. The research findings reveal significant differences in HSPA4 expression across different cancer types, suggesting its diagnostic value and close association with cancer staging and patient survival rates. Furthermore, genetic variations and methylation status of HSPA4 play critical roles in tumorigenesis. Lastly, the interaction of HSPA4 with immune cells is linked to the tumor microenvironment (TME) and immunotherapy. In summary, HSPA4 emerges as a promising cancer biomarker and a vital member of the HSPs family, holding potential applications in diagnosis, prognosis, and immunotherapy. INTRODUCTION The global incidence and mortality rates of cancer have emerged as a grave concern, with the worldwide burden of this affliction exhibiting an escalating trajectory [1] . Elucidating the mechanisms of cancer initiation and developing targeted therapeutic strategies hold significant importance. Historically, chaperone proteins have been posited to assist in the folding and refolding of proteins. When proteins exhibit defects or undergo irreversible misfolding, chaperones perform the dual function of error correction and degradation [2] . As a prominent subclass within the chaperone proteins, heat shock proteins (HSPs) have garnered significant attention in cancer research. Over the past few decades, the field of HSP research has witnessed substantial development and notable progress. Extensive researches on HSP inhibitors and vaccines have been conducted both domestically and internationally, demonstrating significant therapeutic effects [3–5] . Several studies indicate that HSPs play pivotal roles in several cancer-associated features, such as promoting tumor cell growth, supporting angiogenesis, and modulating tumor immune responses [6, 7] . Particularly noteworthy is the ongoing exploration of HSPs ’ therapeutic potential in cancer treatment and immune modulation. Their emerging si

FAQs

Why does the study focus on HSPA4 across multiple cancers?

Prior research covers HSPA4 in specific cancer types, but a comprehensive pan-cancer analysis is lacking, motivating an evaluation across all cancer types.

What does the study use to investigate HSPA4’s role?

The study employs various bioinformatics techniques to assess HSPA4 in diagnosis, prognosis, genetic variation, methylation, and immune-related context.

How is HSPA4 linked to outcomes and cancer biology in this analysis?

Results indicate differential HSPA4 expression across cancer types, associations with cancer staging and survival, and contributions of genetic variation and methylation to tumorigenesis.

Sep 21, 2026

Uploaded by Finn